Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act
Matthew W. Johnson, Roland R. Griffiths, Peter S. Hendricks, et al.
Neuropharmacology (2018) Vol. 142, pp. 143-166
Open Access | Times Cited: 267

Showing 26-50 of 267 citing articles:

Assessing the risk–benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research
David A. Bender, David J. Hellerstein
Psychopharmacology (2022) Vol. 239, Iss. 6, pp. 1907-1932
Closed Access | Times Cited: 64
The therapeutic potential of psilocybin: a systematic review
Jan van Amsterdam, Wim van den Brink
Expert Opinion on Drug Safety (2022) Vol. 21, Iss. 6, pp. 833-840
Closed Access | Times Cited: 58
Neural Mechanisms and Psychology of Psychedelic Ego Dissolution
Devon Stoliker, Gary F. Egan, Karl Friston, et al.
Pharmacological Reviews (2022) Vol. 74, Iss. 4, pp. 876-917
Open Access | Times Cited: 54
Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review
Aryan Sarparast, Kelan Thomas, Benjamin Malcolm, et al.
Psychopharmacology (2022) Vol. 239, Iss. 6, pp. 1945-1976
Open Access | Times Cited: 52
Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms
Emma I Kopra, Jason Ferris, Adam Winstock, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 8, pp. 965-973
Open Access | Times Cited: 44
Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of ‘magic mushroom’ consumption
Emma Morton, Kimberly Sakai, Amir Ashtari, et al.
Journal of Psychopharmacology (2022) Vol. 37, Iss. 1, pp. 49-60
Open Access | Times Cited: 44
Psychedelic-assisted psychotherapy to treat psychiatric and existential distress in life-threatening medical illnesses and palliative care
Stephen Ross, Manish Agrawal, Roland R. Griffiths, et al.
Neuropharmacology (2022) Vol. 216, pp. 109174-109174
Open Access | Times Cited: 41
Novel ethical and policy issues in psychiatric uses of psychedelic substances
William Smith, Paul S. Appelbaum
Neuropharmacology (2022) Vol. 216, pp. 109165-109165
Open Access | Times Cited: 40
Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies
Natacha Perez, Florent Langlest, Luc Mallet, et al.
European Neuropsychopharmacology (2023) Vol. 76, pp. 61-76
Open Access | Times Cited: 39
Ethical and Practical Considerations for the Use of Psychedelics in Psychiatry
Gregory Barber, Charles C. Dike
Psychiatric Services (2023) Vol. 74, Iss. 8, pp. 838-846
Closed Access | Times Cited: 37
Psychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic Industry
Jacob S. Aday, Brian S. Barnett, Dan Grossman, et al.
Psychedelic Medicine (2023) Vol. 1, Iss. 3, pp. 150-165
Closed Access | Times Cited: 22
Psilocybin Exposures Reported to U.S. Poison Centers: National Trends Over a Decade
Rita Farah, Abigail F. Kerns, A. C. MURRAY, et al.
Journal of Adolescent Health (2024) Vol. 74, Iss. 5, pp. 1053-1056
Closed Access | Times Cited: 9
The Global Psychedelic Survey: Consumer characteristics, patterns of use, and access in primarily anglophone regions around the world
Stephanie Lake, Philippe Lucas
International Journal of Drug Policy (2024) Vol. 130, pp. 104507-104507
Closed Access | Times Cited: 8
Pain and Perception: Exploring Psychedelics as Novel Therapeutic Agents in Chronic Pain Management
Natalie Strand, Madeline Whitney, Brooks Johnson, et al.
Current Pain and Headache Reports (2025) Vol. 29, Iss. 1
Closed Access | Times Cited: 1
Self-reported negative outcomes of psilocybin users: A quantitative textual analysis
Bheatrix Bienemann, Nina Stamato Ruschel, Maria Luiza Pesse Campos, et al.
PLoS ONE (2020) Vol. 15, Iss. 2, pp. e0229067-e0229067
Open Access | Times Cited: 68
In vivo production of psilocybin in E. coli
A. Adams, Nicholas A. Kaplan, Zhangyue Wei, et al.
Metabolic Engineering (2019) Vol. 56, pp. 111-119
Closed Access | Times Cited: 63
Rapid-acting antidepressants
Jeffrey M. Witkin, Anna Martin, Lalit K. Golani, et al.
Advances in pharmacology (2019), pp. 47-96
Closed Access | Times Cited: 61
Exploring the case for research on incorporating psychedelics within interventions for borderline personality disorder
Richard J. Zeifman, Anne Catherine Wagner
Journal of Contextual Behavioral Science (2019) Vol. 15, pp. 1-11
Closed Access | Times Cited: 60
The therapeutic potential of microdosing psychedelics in depression
Kim P. C. Kuypers
Therapeutic Advances in Psychopharmacology (2020) Vol. 10
Open Access | Times Cited: 58
Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities
Daniel Rosenbaum, Cory R. Weissman, Thomas Anderson, et al.
Journal of Psychopharmacology (2020) Vol. 34, Iss. 6, pp. 612-622
Closed Access | Times Cited: 54
The emerging role of psilocybin and MDMA in the treatment of mental illness
Hartej Gill, Barjot Gill, David Chen‐Li, et al.
Expert Review of Neurotherapeutics (2020) Vol. 20, Iss. 12, pp. 1263-1273
Closed Access | Times Cited: 54
Psychedelics as an emerging novel intervention in the treatment of substance use disorder: a review
Alec James Divito, Robert F Leger
Molecular Biology Reports (2020) Vol. 47, Iss. 12, pp. 9791-9799
Closed Access | Times Cited: 54
Associations between lifetime classic psychedelic use and markers of physical health
Otto Simonsson, James Sexton, Peter S. Hendricks
Journal of Psychopharmacology (2021) Vol. 35, Iss. 4, pp. 447-452
Open Access | Times Cited: 54
From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders
Urszula Kozłowska, Charles D. Nichols, Kalina Wiatr, et al.
Journal of Neurochemistry (2021) Vol. 162, Iss. 1, pp. 89-108
Open Access | Times Cited: 51
Psychedelic therapy: a roadmap for wider acceptance and utilization
Mason Marks, I. Glenn Cohen
Nature Medicine (2021) Vol. 27, Iss. 10, pp. 1669-1671
Open Access | Times Cited: 50

Scroll to top